Fluvastatin

76 interactions 277 cited references

Also sold as: Lescol Lescol® Lescol® XL

About Fluvastatin

Fluvastatin is used together with diet, weight loss, and exercise to reduce the risk of heart attack and stroke and to decrease the chance that heart surgery will be needed in people who have heart disease or who are at risk of developing heart disease. Fluvastatin is also used to decrease the amount of fatty substance… Read the full Fluvastatin drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Posaconazole Letermovir Meloxicam Injection Meloxicam Danazol Leniolisib

1 Contraindicated 46 Major 24 Moderate 5 Minor

All (76) Contraindicated (1) Major (46) Moderate (24) Minor (5)

Contraindicated

Fluvastatin Posaconazole Noxafil Increased fluvastatin plasma concentration and increased risk of myopathy or rhabdomyolysis Details

Major

Fluvastatin Capecitabine Xeloda Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Fluvastatin Cyclosporine Injection Atopica Increased fluvastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Fluvastatin Cyclosporine Ophthalmic Cequa Increased fluvastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Fluvastatin Danazol Danocrine® An increased risk of myopathy or rhabdomyolysis Details Fluvastatin Daptomycin Cubicin Increased risk of myopathy or rhabdomyolysis Details Fluvastatin Daptomycin Injection Cubicin Increased risk of myopathy or rhabdomyolysis Details Fluvastatin Darolutamide Nubeqa Increased exposure of OATP1B1 or OATP1B3 substrates Details Fluvastatin Entacapone Comtan Increased exposure of CYP2C9 substrate Details Fluvastatin Fluorouracil Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Fluvastatin Fluorouracil Injection Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Fluvastatin Fluorouracil Topical Carac Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Fluvastatin Apalutamide Erleada Reduced OATP1B1/CYP2C9 substrates exposure Details Fluvastatin Atazanavir Reyataz Increased HMG-CoA reductase inhibitor exposure Details Fluvastatin Bezafibrate Increased incidence and severity of myopathy Details Fluvastatin Carbamazepine Carbatrol Reduced CYP2C9 substrate exposure and reduced efficacy of CYP2C9 substrate Details Fluvastatin Ceritinib Zykadia Increased exposure of CYP2C9 substrate Details Fluvastatin Ciprofibrate An increased risk of myopathy or rhabdomyolysis Details Fluvastatin Clarithromycin Biaxin Increased fluvastatin exposure and an increased risk of fluvastatin-related adverse events (increased risk of fluvastatin toxiciti... Details Fluvastatin Clofibrate An increased risk of myopathy and rhabdomyolysis Details Fluvastatin Cobicistat Tybost Increased HMG-CoA reductase inhibitor that also are OATP1B1/B3 substrates exposure Details Fluvastatin Cyclosporine Atopica Increased fluvastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Fluvastatin Dalfopristin An increased risk of myopathy or rhabdomyolysis Details Fluvastatin Darunavir Increased HMG-CoA reductase inhibitors exposure Details Fluvastatin Deutivacaftor Increased CYP2C9 substrate exposure Details Fluvastatin Doxifluridine Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Fluvastatin Elafibranor Iqirvo Increased risk of CPK elevation/myalgia and an increased risk of myopathy Details Fluvastatin Elexacaftor Increased OATP1B1/OATP1B3 substrate exposure Details Fluvastatin Eltrombopag Alvaiz Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions Details Fluvastatin Fenofibrate Antara An increased risk of myopathy and rhabdomyolysis Details Fluvastatin Fenofibric Acid Fibricor An increased risk of myopathy and rhabdomyolysis Details Fluvastatin Fluconazole Diflucan Increased fluvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Fluvastatin Fosphenytoin Cerebyx Increased phenytoin or fosphenytoin (prodrug of phenytoin) exposure, increased risk of phenytoin or fosphenytoin toxicity and redu... Details Fluvastatin Gemfibrozil Lopid An increased risk of myopathy or rhabdomyolysis Details Fluvastatin Leniolisib Joenja Increased OATP1B1/OATP1B3 substrate exposure Details Fluvastatin Letermovir Prevymis Increased fluvastatin exposure and an increased risk for myopathy and rhabdomyolysis Details Fluvastatin Meloxicam Alloxate Increased meloxicam exposure and reduced meloxicam metabolic clearance Details Fluvastatin Phenobarbital Fidoquel Reduced CYP2C9 substrate exposure and reduced efficacy of CYP2C9 substrate Details Fluvastatin Phenytoin Dilantin Increased phenytoin or fosphenytoin (prodrug of phenytoin) exposure, increased risk of phenytoin or fosphenytoin toxicity and redu... Details Fluvastatin Pixantrone Increased exposure of CYP2C8 substrates Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.